Norfolk Southern to announce second quarter 2026 earnings results on July 23, 2026
Get Alerts NSC Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.6%
Revenue Growth %: +6.1%
Join SI Premium – FREE
What: | Norfolk Southern Second Quarter 2026 Earnings Conference Call |
When: | |
How to Participate: | Teleconference: 1-800-836-8184 (Dial in several minutes prior to call start). Live webcast: Via Webcast (Link is also available in the Investors section of the company's website) |
Replay: | Following the live broadcast, a replay will be available via web link in the Investors section of the company's website. |
For electronic notification of earnings events, subscribe to Investor Alerts, an email distribution list for the latest investor events, reports, news and more from Norfolk Southern.
About Norfolk Southern
Since 1827, Norfolk Southern Corporation (NYSE: NSC) and its predecessor companies have safely moved the goods and materials that drive the U.S. economy. Today, it operates a 22-state freight transportation network. Committed to furthering sustainability, Norfolk Southern helps its customers avoid approximately 15 million tons of yearly carbon emissions by shipping via rail. Its dedicated team members deliver approximately 7 million carloads annually, from agriculture to consumer goods. Norfolk Southern also has the most extensive intermodal network in the eastern U.S. It serves a majority of the country's population and manufacturing base, with connections to every major container port on the Atlantic coast as well as major ports across the Gulf Coast and Great Lakes. Learn more by visiting www.NorfolkSouthern.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/norfolk-southern-to-announce-second-quarter-2026-earnings-results-on-july-23-2026-302811014.html
SOURCE Norfolk Southern Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T-Mobile (TMUS) Tops Q2 EPS by 27c; offers outlook
- Ryder Reports Second Quarter 2026 Results
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share